会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF
    • PRODRUG化合物及其制备方法
    • WO0033888A3
    • 2001-11-08
    • PCT/US9930393
    • 1999-12-10
    • COULTER PHARM INCLOBL THOMAS JDUBOIS VINCENTFERNANDEZ ANNE MARIEGANGWAR SANJEEVLEWIS EVANNIEDER MATTHEW HTROUET ANDREVISKI PETERYARRANTON GEOFFREY T
    • LOBL THOMAS JDUBOIS VINCENTFERNANDEZ ANNE-MARIEGANGWAR SANJEEVLEWIS EVANNIEDER MATTHEW HTROUET ANDREVISKI PETERYARRANTON GEOFFREY T
    • A61K31/138A61K31/165A61K31/198A61K31/337A61K31/407A61K31/437A61K31/4745A61K31/513A61K31/519A61K31/52A61K31/5517A61K31/555A61K31/7004A61K31/7028A61K31/7048A61K31/7064A61K31/7068A61K33/24A61K47/42A61K47/48A61P29/00A61P35/00C07K5/10C07K7/00
    • A61K47/65
    • The compound of the invention is a prodrug form of a therapeutic agent linked directly or indirectly to an oligopeptide, which in turn, is linked to a stabilizing group. More generally, the present invention may be described as a new prodrug compound of a therapeutic agent, especially prodrugs comprising an antitumor therapeutic agent, displaying improved therapeutic properties relative to the products of the prior art, especially improved therapeutic properties in the treatment of cancerous tumors and/or in the treatment of inflammatory reactions such as rheumatic diseases. Improved therapeutic properties include decreased toxicity and increased efficacy. Particularly desired are prodrugs which display a high specificity of action, a reduced toxicity, an improved stability in the serum and blood, and which do not move into target cells until activated by a target cell associated enzyme. Prodrug compounds of a marker enabling tumors to be characterized (diagnosis, progression of the tumor, assay of the factors secreted by tumor cells, etc.) are also contemplated. The present invention also relates to the pharmaceutical composition comprising the compound according to the invention and optionally a pharmaceutically acceptable adjuvant or vehicle. Further, a method of decreasing toxicity by modifying a therapeutic agent to create a prodrug is disclosed. Several processes for creating a prodrug of the invention are described. Compounds of the invention include the prodrugs, Suc-ssAla-Leu-Ala-Leu-Dox, Suc-ssAla-Leu-Ala-Leu-Dnr, and Glutaryl-ssAla-Leu-Ala-Leu-Dox. Additionally intermediate compounds, important to the process of preparation of the prodrugs of the invention are claimed.
    • 本发明的化合物是与寡肽直接或间接连接的治疗剂的前药形式,其又与稳定基团连接。 更一般地,本发明可以描述为治疗剂的新的前药化合物,特别是包含抗肿瘤治疗剂的前药,相对于现有技术的产品显示出改善的治疗性质,特别是治疗癌性肿瘤的改善的治疗性质 和/或治疗诸如风湿性疾病的炎性反应。 改进的治疗性质包括毒性降低和功效增加。 特别期望的是显示出高度的作用特异性,毒性降低,血清和血液中改善的稳定性,并且不会移动到靶细胞中直到被靶细胞相关的酶活化的前药。 还考虑了能够表征肿瘤(诊断,肿瘤进展,肿瘤细胞分泌的因子的测定等)的标记物的前药化合物。 本发明还涉及包含根据本发明的化合物和任选的药学上可接受的佐剂或赋形剂的药物组合物。 此外,公开了通过修饰治疗剂以产生前药来降低毒性的方法。 描述了用于制备本发明的前药的几种方法。 本发明的化合物包括前体药物Suc-ssAla-Leu-Ala-Leu-Dox,Suc-ssAla-Leu-Ala-Leu-Dnr和Glutaryl-ssAla-Leu-Ala-Leu-Dox。 要求保护本发明前药制备方法重要的中间体化合物。
    • 2. 发明申请
    • METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES
    • 合成苯丙胺 - 肽共聚物的方法
    • WO2004011033A1
    • 2004-02-05
    • PCT/EP2003/008082
    • 2003-07-23
    • UNIVERSITE CATHOLIQUE DE LOUVAINDIATOS S.A.FERNANDEZ, Anne-MarieDUBOIS, Vincent
    • FERNANDEZ, Anne-MarieDUBOIS, Vincent
    • A61K47/48
    • C07H15/252A61K47/64A61K47/65
    • The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of: a) halogenating a compound of formula (II), resulting in compound of formula (IIa), b) reacting a compound of formula (IIa) at its 14 position with the thiol moiety of a peptide of formula (III), optionally in the presence of a suitable linker, to obtain said compound of formula (I), wherein R 1 represents OH, NH 2 or NH-peptide; R 2 represents H or -CO-peptide; R 3 represents OCH 3 , OH or H; R 4 represents H, or COCF 3 ; R 5 represents OH, O-tetrahydropyranyl or H; R 6 represents OH or H; R 7 represents H, OH, OCO(CH 2 ) 3 CH 3 or OCOCH(OC 2 H 5 ) 2 ; R 8 represents OH or H; R 9 represents OH or H; R 10 represents a halogen and L is an optional suitable linker arm.
    • 本发明涉及制备式(I)化合物或其药学上可接受的盐及其中间体的方法,包括以下步骤:a)将式(II)化合物卤化,得到式(IIa)化合物 ),b)任选地在合适的连接基存在下,使式(IIa)化合物在其14位与式(III)的肽的硫醇部分反应,得到所述式(I)的化合物,其中R 1 代表OH,NH2或NH-肽; R 2表示H或-CO-肽; R 3表示OCH 3,OH或H; R 4表示H或COCF 3; R 5表示OH,O-四氢吡喃基或H; R 6表示OH或H; R 7表示H,OH,OCO(CH 2)3 CH 3或OCOCH(OC 2 H 5)2; R 8表示OH或H; R 9表示OH或H; R 10表示卤素,L是任选的合适的连接臂。